Infectious Disease Oral Biosensor Function Confirmed
Jun 29, 2020
Vancouver, Canada (June 29, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its diagnostic...
Infectious Disease Oral Screening Test Advancement
Jun 15, 2020
Vancouver, Canada (June 15, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its wholly...
Diagnostic Partner 3a Receives BMBF Grant for Infectious Disease Screening Tests
Jun 10, 2020
Vancouver, Canada (June 10, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its diagnostic...
Parkinson’s Generic Transdermal Drug Delivery System
Jun 8, 2020
Vancouver, Canada (June 8, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its wholly...
Exclusive Agreement with Oettinger Brewery for Cannabis-Infused Beverages signed
May 12, 2020
Vancouver, Canada (May 12, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that it has...
Infectious Disease Oral Dissolvable Biosensor Development
Apr 22, 2020
Vancouver, Canada (April 22, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that further to...
COVID-19 Screening Test, Oral Thin Film Biosensor Products and Identification Platform
Apr 20, 2020
Vancouver, Canada (April 20, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that it has...
Exclusive Advisory Agreement for COVID-19 and Host Cell Interactions Signed
Mar 25, 2020
Vancouver, Canada (March 25, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that an exclusive infectious disease...
COVID-19 Test and Development Programs Update
Mar 20, 2020
Vancouver, Canada (March 20, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce updates to its infectious disease...
Update on XPhyto’s Epilepsy Treatment Program
Mar 18, 2020
Vancouver, Canada (March 18, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce significant progress with respect to development...
XPhyto Initiates Infectious Disease Programs
Mar 3, 2020
Vancouver, Canada (March 03, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that its wholly owned German subsidiary,...
Exclusive Strategic Partnership Commenced with Elite Bavarian Brewing & Beverage Institute Weihenstephan (TUM)
Feb 18, 2020
Vancouver, Canada (February 18, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that its wholly owned German subsidiary,...
